Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.

Y. Okada, H. Anai, T. Hattori, Yoshihiko Maehara, J. Nishimura, K. Sugimachi, H. Nawata

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Seventeen consecutively treated patients with advanced gastric cancer were prescribed every 3 weeks intravenous cisplatin (20 mg/m2/day) and a continuous infusion of 5-fluorouracil (5-FU) (750 mg/m2/day) for 5 days. Twelve (71%) patients had been treated previously with other anticancer drugs. Seven (42%) patients showed a partial response and these responses persisted for over 4.4 months. Stabilization of the disease occurred in eight (47%) patients, and in two (12%) the disease progressed. At the time of analysis, mean survival of the responders was 8.2 months, while that of non-responders was 5.0 months. The toxicities were within acceptable limits and only a few had a grade III toxicity. This combined administration of cisplatin and 5-FU for 5 days is safe and effective for patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)453-456
Number of pages4
JournalAnti-cancer drugs
Volume2
Issue number5
DOIs
Publication statusPublished - Jan 1 1991

Fingerprint

Fluorouracil
Cisplatin
Stomach Neoplasms
Survival Rate
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Cite this

Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer. / Okada, Y.; Anai, H.; Hattori, T.; Maehara, Yoshihiko; Nishimura, J.; Sugimachi, K.; Nawata, H.

In: Anti-cancer drugs, Vol. 2, No. 5, 01.01.1991, p. 453-456.

Research output: Contribution to journalArticle

Okada, Y, Anai, H, Hattori, T, Maehara, Y, Nishimura, J, Sugimachi, K & Nawata, H 1991, 'Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.', Anti-cancer drugs, vol. 2, no. 5, pp. 453-456. https://doi.org/10.1097/00001813-199110000-00003
Okada, Y. ; Anai, H. ; Hattori, T. ; Maehara, Yoshihiko ; Nishimura, J. ; Sugimachi, K. ; Nawata, H. / Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer. In: Anti-cancer drugs. 1991 ; Vol. 2, No. 5. pp. 453-456.
@article{a525b799939d428f800a018ef48c4504,
title = "Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.",
abstract = "Seventeen consecutively treated patients with advanced gastric cancer were prescribed every 3 weeks intravenous cisplatin (20 mg/m2/day) and a continuous infusion of 5-fluorouracil (5-FU) (750 mg/m2/day) for 5 days. Twelve (71{\%}) patients had been treated previously with other anticancer drugs. Seven (42{\%}) patients showed a partial response and these responses persisted for over 4.4 months. Stabilization of the disease occurred in eight (47{\%}) patients, and in two (12{\%}) the disease progressed. At the time of analysis, mean survival of the responders was 8.2 months, while that of non-responders was 5.0 months. The toxicities were within acceptable limits and only a few had a grade III toxicity. This combined administration of cisplatin and 5-FU for 5 days is safe and effective for patients with advanced gastric cancer.",
author = "Y. Okada and H. Anai and T. Hattori and Yoshihiko Maehara and J. Nishimura and K. Sugimachi and H. Nawata",
year = "1991",
month = "1",
day = "1",
doi = "10.1097/00001813-199110000-00003",
language = "English",
volume = "2",
pages = "453--456",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Cisplatin plus continuous infusion of 5-fluorouracil for 5 days effective for patients with advanced gastric cancer.

AU - Okada, Y.

AU - Anai, H.

AU - Hattori, T.

AU - Maehara, Yoshihiko

AU - Nishimura, J.

AU - Sugimachi, K.

AU - Nawata, H.

PY - 1991/1/1

Y1 - 1991/1/1

N2 - Seventeen consecutively treated patients with advanced gastric cancer were prescribed every 3 weeks intravenous cisplatin (20 mg/m2/day) and a continuous infusion of 5-fluorouracil (5-FU) (750 mg/m2/day) for 5 days. Twelve (71%) patients had been treated previously with other anticancer drugs. Seven (42%) patients showed a partial response and these responses persisted for over 4.4 months. Stabilization of the disease occurred in eight (47%) patients, and in two (12%) the disease progressed. At the time of analysis, mean survival of the responders was 8.2 months, while that of non-responders was 5.0 months. The toxicities were within acceptable limits and only a few had a grade III toxicity. This combined administration of cisplatin and 5-FU for 5 days is safe and effective for patients with advanced gastric cancer.

AB - Seventeen consecutively treated patients with advanced gastric cancer were prescribed every 3 weeks intravenous cisplatin (20 mg/m2/day) and a continuous infusion of 5-fluorouracil (5-FU) (750 mg/m2/day) for 5 days. Twelve (71%) patients had been treated previously with other anticancer drugs. Seven (42%) patients showed a partial response and these responses persisted for over 4.4 months. Stabilization of the disease occurred in eight (47%) patients, and in two (12%) the disease progressed. At the time of analysis, mean survival of the responders was 8.2 months, while that of non-responders was 5.0 months. The toxicities were within acceptable limits and only a few had a grade III toxicity. This combined administration of cisplatin and 5-FU for 5 days is safe and effective for patients with advanced gastric cancer.

UR - http://www.scopus.com/inward/record.url?scp=0026236994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026236994&partnerID=8YFLogxK

U2 - 10.1097/00001813-199110000-00003

DO - 10.1097/00001813-199110000-00003

M3 - Article

C2 - 1804387

AN - SCOPUS:0026236994

VL - 2

SP - 453

EP - 456

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -